error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart
Back to Article Listing Page
Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System Now Compatible on Android Smart Phones and Watches in Europe

EDINBURGH, Scotland, January 10, 2017 - DexCom, Inc. (NASDAQ:DXCM), the leader in Continuous Glucose Monitoring (CGM) for patients with diabetes, announced today that its G5 Mobile CGM System is now compatible on Android smart devices throughout Europe and South Africa. This new platform will be launching into select European countries today and continue throughout the fourth quarter of 2017.


The G5 Mobile CGM System is now the world’s first CE marked mobile CGM system that is compatible on both iOS and Android platforms. The significant milestone provides European patients with greater access to Dexcom’s world-class CGM technology. European sales and usage data2 show that Android compatible smart phones have a 45% market share in the UK, and more than 60% market share in Germany, Italy, France and the Netherlands. European patients who already have or are looking to acquire a compatible Android smart device will now be able to use that device to access Dexcom’s G5 Mobile CGM System.


In addition to the Android platform launch across Europe, the Dexcom G5 Mobile Receiver will now become an optional display device for users and will no longer be required as a component of the G5 Mobile CGM System. This enhancement could mean significant savings for patients and further breaks down barriers, giving access to Dexcom’s G5 Mobile System.


"Dexcom is rapidly advancing technology for continuous glucose monitoring devices to improve diabetes management. These advances are making diabetes management more convenient and flexible than ever before," stated John Lister, General Manager EMEA, of Dexcom. "We are excited for the promise our CGM technology holds for patients and caregivers and we are excited to be able to further expand our offerings into European markets."

Dexcom Announces FDA Approval of G5 Mobile App for Android Devices

Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy

Media Inquiries

Julia Yuryev


Investor Relations

Steve Pacelli

Images & Media

Media Kit